Xilio Therapeutics (XLO) Profit After Tax (2020 - 2026)

Xilio Therapeutics has disclosed Profit After Tax across 7 years of filings, most recently posting -$14.1 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$14.1 million, down 6.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$42.2 million (up 22.28% YoY), and the FY2025 annual result was -$42.0 million, up 27.92% from the prior year.
• Profit After Tax came in at -$14.1 million for Q1 2026 at Xilio Therapeutics, down from -$11.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$1.9 million in Q3 2025 to a low of -$24.6 million in Q2 2022.
• The 5-year median for Profit After Tax is -$16.7 million (2023), against an average of -$16.4 million.
• Across the five-year window, Profit After Tax declined 28.12% in 2022 and jumped 86.24% in 2025, its largest moves.
• Xilio Therapeutics' Profit After Tax stood at -$22.4 million in 2022, then rose by 20.98% to -$17.7 million in 2023, then gained by 25.76% to -$13.1 million in 2024, then gained by 9.93% to -$11.8 million in 2025, then slipped by 19.23% to -$14.1 million in 2026.
• The last three Profit After Tax figures came in at -$14.1 million (Q1 2026), -$11.8 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.